Skip to main content
Premium Trial:

Request an Annual Quote

Invitae, Nanopharmacia Partner on Genetic Cancer Testing in Mexico, Costa Rica, Panama

NEW YORK (GenomeWeb) – Invitae and Nanopharmacia today announced an exclusive partnership to provide access to Invitae's genetic tests for hereditary cancers in Mexico.

The deal also will make Invitae's tests available on a non-exclusive basis in Costa Rica and Panama. Financial and other terms were not disclosed.

Nanopharmacia, a provider of cancer molecular tests in Mexico and Latin America, will make Invitae's tests available to onco-geneticists and medical and surgical oncologists. Invitae offers single-gene BRCA1/2 testing, including full gene sequencing and deletion/duplication analysis, as well as a six-gene, high-risk hereditary breast cancer panel.

The San Francisco-based firm also offers an 18-gene women's hereditary cancer panel covering hereditary breast, ovarian, and endometrial cancer; a 29-gene hereditary cancer syndrome panel; a 17-gene hereditary pancreatic cancer panel; and other hereditary panels covering cancers including Lynch syndrome and colon cancers.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.